Biologics are protein-based antibody drugs used to treat cancers, autoimmune disorders, and other chronic diseases. Comprised of very large molecules and typically delivered intravenously in high concentrations over several hours, these therapeutics are usually administered in hospitals settings or infusion clinics. Arsia Therapeutics’ mission is to improve access to these life-saving drugs, make them more patient-friendly, and reduce healthcare costs by enabling subcutaneous delivery in non-hospital settings. Arsia’s proprietary technology to make injectable formulations of high-concentration antibody drugs can be applied to existing branded biologics, biosimilars, as well as biologics in development.
- Robert Langer, PhD Co-Founder
- Amy Schulman Chief Executive Officer
- Alan Crane Co-Founder & President
- Charles Wescott Vice President, Research & Development